logo
Share SHARE
FONT-SIZE Plus   Neg

Gilead Sciences' Truvada Gets FDA Priority Review - Quick Facts

Gilead Sciences Inc. (GILD) Monday said U.S Food and Drug Administration has accepted the supplemental New Drug Application and granted a six-month priority review for once-daily Truvada to reduce the risk of HIV-1 infection among uninfected adults.

Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.

The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists.

Truvada is not currently indicated to reduce the risk of HIV infection.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
President Donald Trump has continued his assault on one of his favorite targets on Wednesday, lashing out at major media outlets in a series of posts on Twitter. Trump singled out the New York Times and the Washington Post in his tweets, describing the newspapers as "fake news." Christoph, born on-board a Spirit flight destined to Dallas from Fort Lauderdale airport, can celebrate all his forthcoming birthdays in life with a free travel on Spirit airline. Blue Apron Holdings Inc. has cut the expected price range for its initial public offering amid worries about the potential impact on the food retail sector of Amazon.com Inc.'s recent deal to buy grocery chain Whole Foods Market Inc. for $13.7 billion.
comments powered by Disqus
Follow RTT